Search Results

You are looking at 91 - 100 of 135 items for :

Clear All
Full access

Wei Wang, Guilin Tang, Tapan Kadia, Xinyan Lu, Yan Li, Lanshan Huang, Ximena Montenegro-Garreaud, Roberto N. Miranda and Sa A. Wang

to be resistant to tyrosine kinase inhibitor (TKI) treatment. Recent studies have demonstrated that the third-generation TKI ponatinib may be effective in treating these patients. 20 In our case, intensive chemotherapy eradicated the transformed

Full access

Patrick Brown, Hiroto Inaba, Colleen Annesley, Jill Beck, Susan Colace, Mari Dallas, Kenneth DeSantes, Kara Kelly, Carrie Kitko, Norman Lacayo, Nicole Larrier, Luke Maese, Kris Mahadeo, Ronica Nanda, Valentina Nardi, Vilmarie Rodriguez, Jenna Rossoff, Laura Schuettpelz, Lewis Silverman, Jessica Sun, Weili Sun, David Teachey, Victor Wong, Gregory Yanik, Alyse Johnson-Chilla and Ndiya Ogba

. 22 , 59 , 60 Genomic profiling studies have found that at least 80% of Ph-like ALL cases have cytokine receptor- or kinase-activating alterations, suggesting potential for ABL -class tyrosine kinase inhibitors (TKIs) or JAK small molecule inhibitors

Full access

Jacqueline N. Poston and Pamela S. Becker

inhibitors (TKIs) or omacetaxine is not infrequent, although no randomized trials have explored this issue. Heim et al 50 described the use of G-CSF given 3 times weekly in 6 patients with neutropenia on imatinib. Akard et al 51 described frequent grade 3

Full access

David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN and Miranda Hughes

analysis (IMpower150) reported that subsequent therapy with the ABCP regimen improved survival in 26 patients with EGFR mutation–positive metastatic NSCLC whose disease had progressed after first-line EGFR tyrosine kinase inhibitor (TKI) therapy compared

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer and Rashmi Kumar

investigators was 7.6 months (95% CI, 5.6-15.2). However, at the 2013 European Society for Medical Oncology (ESMO) annual meeting, central review showed a median PFS of only 3.7 months. 13 Tyrosine Kinase Inhibitors The tyrosine kinase inhibitors (TKIs

Full access

Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan and Steven Brem

neutralize all VEGF ligands to produce clinical benefit. In contrast, VEGFR tyrosine kinase inhibitor (TKI) probably operates in a linear fashion, and antiangiogenesis may occur only when nearly all of the receptors are individually blocked. This concept is

Full access

leukemia (CML) can be maintained chronically via tyrosine kinase inhibitor (TKI) therapy, and adherence to therapy is important to reduce the risk of disease recurrence and progression. Current guidelines recommend routine polymerase chain reaction (PCR

Full access

Joseph C. Alvarnas and Patrick A. Brown

therapeutic strategies for individual patients, exemplifying the extraordinary potential of “precision medicine.” The use of targeted therapeutic agents, such as tyrosine kinase inhibitors (TKI) for patients with Philadelphia chromosome (Ph)–positive ALL, and

Full access

Diane Reidy and Leonard Saltz

tyrosine kinase inhibitor (TKI) gefitinib (G) in patients with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC) [abstract] . J Clin Oncol 2006 ; 24 ( Suppl 1 ): 122s . Abstract 3006 . 40. LeRoith D Helman

Full access

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada and Eddy S. Yang

amplifications of MET, EGFR , and CDK6 of unclear clinical significance. This new information was brought again to the UAB MTB for discussion. Tyrosine kinase inhibitors (TKIs) were considered but not recommended due to the downstream activating mutation of